These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12556205)

  • 1. Analysing p53 tumour suppressor functions in mice.
    Sluss HK; Jones SN
    Expert Opin Ther Targets; 2003 Feb; 7(1):89-99. PubMed ID: 12556205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-translational modification of p53 in tumorigenesis.
    Bode AM; Dong Z
    Nat Rev Cancer; 2004 Oct; 4(10):793-805. PubMed ID: 15510160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
    Stein T; Crighton D; Boyle JM; Varley JM; White RJ
    Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53--an acrobat in tumorigenesis.
    Moll UM; Schramm LM
    Crit Rev Oral Biol Med; 1998; 9(1):23-37. PubMed ID: 9488246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein.
    Warnock LJ; Knox A; Mee TR; Raines SA; Milner J
    Cancer Biol Ther; 2008 Sep; 7(9):1481-9. PubMed ID: 18769132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcription-independent suppression of DNA synthesis by p53 in sperm-irradiated mouse zygotes.
    Toyoshima M; Shimura T; Adiga SK; Taga M; Shiraishi K; Inoue M; Yuan ZM; Niwa O
    Oncogene; 2005 May; 24(20):3229-35. PubMed ID: 15735681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor p53: regulation and function.
    Somasundaram K
    Front Biosci; 2000 Apr; 5():D424-37. PubMed ID: 10762600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.
    Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
    Oncogene; 2001 Sep; 20(39):5503-10. PubMed ID: 11571648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for manipulating the p53 pathway in the treatment of human cancer.
    Hupp TR; Lane DP; Ball KL
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
    Aubrey BJ; Kelly GL; Janic A; Herold MJ; Strasser A
    Cell Death Differ; 2018 Jan; 25(1):104-113. PubMed ID: 29149101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational regulation of p53 tumor suppressor protein function.
    Maxwell SA; Roth JA
    Crit Rev Oncog; 1994; 5(1):23-57. PubMed ID: 7948107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.
    Wang XW; Harris CC
    Cancer Surv; 1996; 28():169-96. PubMed ID: 8977035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-translational modifications and activation of p53 by genotoxic stresses.
    Appella E; Anderson CW
    Eur J Biochem; 2001 May; 268(10):2764-72. PubMed ID: 11358490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subcellular distribution of the p53 tumour suppressor, and organismal ageing.
    Wesierska-Gadek J; Schmid G
    Cell Mol Biol Lett; 2005; 10(3):439-53. PubMed ID: 16217555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.